Even though the medical relevance with the aforementioned cardiovascular danger factor alterations by tirzepatide will be assessed in the planned cardiovascular outcome study SURPASS-CVOT ( "kind":"medical-trial","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-analysis indicated tha